The present disclosure provides a crRNA comprising a spacer sequence that is capable of hybridizing to a target RNA sequence, wherein the target RNA sequence is within at least one hepatitis B virus (HBV) transcript, wherein the HBV transcript is selected from the group consisting of pre-core mRNA (pcRNA), pre-genomic RNA (pgRNA), pre-S mRNA, S mRNA, and X mRNA. In some embodiments, there is also provided RNA editing systems comprising the crRNAs disclosed herein, pharmaceutical compositions comprising the crRNAs or RNA editing systems disclosed herein, and methods for the treatment of a HBV infection using the crRNAs or RNA editing systems disclosed herein.
A61K 39/295 - Antigènes viraux polyvalentsMélanges d'antigènes viraux et bactériens
C12Q 1/70 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des virus ou des bactériophages
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 39/385 - Haptènes ou antigènes, liés à des supports
C07K 14/005 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de virus
A61P 31/20 - Antiviraux pour le traitement des virus ADN
C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification
The technology relates to the use of at least macrocyclic lactone such as ivermectin or moxidectin to inhibit a coronavirus in a subject in order to treat, prevent or reduce the risk of infection by the coronavirus.
The technology relates to the use of at least one macrocyclic lactone such as ivermectin or moxidectin to inhibit a coronavirus in a subject in order to treat, prevent or reduce the risk of infection by the coronavirus.
A61K 31/7048 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'oxygène comme hétéro-atome d'un cycle, p. ex. leucoglucosane, hespéridine, érythromycine, nystatine
The technology relates to the use of at least macrocyclic lactone such as ivermectin or moxidectin to inhibit a coronavirus in a subject in order to treat, prevent or reduce the risk of infection by the coronavirus.
WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (Australie)
GRAINS RESEARCH AND DEVELOPMENT CORPORATION (Australie)
MELBOURNE HEALTH (Australie)
Inventeur(s)
Tanner, Gregory John
Howitt, Crispin Alexander
Abrégé
The present invention relates to methods of producing a food or malt-base beverage suitable for consumption by a subject with Coeliac's disease. In particular, the present invention relates to methods of producing a food or malt-based beverage with low levels of hordeins. Also provided are barley plants which produce grain that can be used in the methods of the invention.
The present invention relates to the identification of a profile of antibodies in an individual with chronic hepatitis B (CHB) wherein the existence of this profile is indicative that the individual will achieve or has achieved a functional cure (FC). The present invention further identifies an epitope profile or profile on Hepatitis B virus surface antigen (HBsAg) which represents targets for antibodies which enable a level of clearance to be achieved to reach a functional cure for CHB. Level of occupancy of the epitope profile is indicative that a functional cure will or will not be achieved.
G01N 33/576 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour l'hépatite
G01N 33/564 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour complexes immunologiques préexistants ou maladies auto-immunes
09 - Appareils et instruments scientifiques et électriques
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Downloadable software application using music and guided sessions to promote relaxation, reduction of stress and anxiety, and mental and emotional health Online provision of an internet web based portal using music and guided sessions to promote relaxation, reduction of stress and anxiety, and mental and emotional health; online provision of an internet web based portal for health practitioners in the field of mental and emotional health and relaxation therapy
Walter and Eliza Hall Institute of Medical Research (Australie)
Grains Research and Development Corporation (Australie)
Melbourne Health (Australie)
Inventeur(s)
Tanner, Gregory John
Howitt, Crispin Alexander
Abrégé
The present invention relates to methods of producing a food or malt-base beverage suitable for consumption by a subject with Coeliac's disease. In particular, the present invention relates to methods of producing a food or malt-based beverage with low levels of hordeins. Also provided are barley plants which produce grain that can be used in the methods of the invention.
Commonwealth Scientific and Industrial Research Organisation (Australie)
Walter and Eliza Hall Institute of Medical Research (Australie)
Grains Research and Development Corporation (Australie)
Melbourne Health (Australie)
Inventeur(s)
Tanner, Gregory John
Howitt, Crispin Alexander
Abrégé
The present invention relates to methods of producing a food or malt-base beverage suitable for consumption by a subject with Coeliac's disease. In particular, the present invention relates to methods of producing a food or malt-based beverage with low levels of hordeins. Also provided are barley plants which produce grain that can be used in the methods of the invention.
Walter and Eliza Hall Institute of Medical Research (Australie)
Grains Research and Development Corporation (Australie)
Melbourne Health (Australie)
Inventeur(s)
Tanner, Gregory John
Howitt, Crispin Alexander
Abrégé
The present invention relates to methods of producing a food or malt-base beverage suitable for consumption by a subject with Coeliac's disease. In particular, the present invention relates to methods of producing a food or malt-based beverage with low levels of hordeins. Also provided are barley plants which produce grain that can be used in the methods of the invention.
A01H 1/00 - Procédés de modification des génotypes
A01H 5/00 - Angiospermes, c.-à-d. plantes à fleurs, caractérisées par leurs parties végétalesAngiospermes caractérisées autrement que par leur taxonomie botanique
The present invention relates generally to biomarkers of neurological conditions including monitoring disease progression and the clinical severity of symptoms. More particularly, the present invention provides an assay to facilitate diagnosis and monitoring of progression of neurological conditions and treatment response and to identify targets for therapeutic intervention. Kits and assays for diagnosis and identification of medicaments also form part of the present invention.
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
G01N 33/48 - Matériau biologique, p. ex. sang, urineHémocytomètres
The present invention relates generally to diagnostic assays, therapeutic protocols and medicinal predictor model validation. More particularly, genetic tests are provided which determine the suitability of a medicament in the treatment or prophylaxis of a neurological condition. Even more particularly, the present invention provides genetic assays to measure the potential for, or likelihood of, a subject having a positive or adverse treatment response to a neurological medicament. The present invention is particularly useful in the practice of personalized medicine.
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
C12N 15/00 - Techniques de mutation ou génie génétiqueADN ou ARN concernant le génie génétique, vecteurs, p. ex. plasmides, ou leur isolement, leur préparation ou leur purificationUtilisation d'hôtes pour ceux-ci
16.
MARINE-ANIMAL DERIVED THERAPEUTIC AND DIAGNOSTIC AGENTS FOR HEPATITIS B
The present invention relates generally to cartilaginous marine animal-derived immunoglobulin-like molecules which bind to a Hepatitis B virus (HBV) antigen or precursor or processed form thereof including a monomeric or multimeric form thereof or an antigenic fragment thereof and their use in therapeutic and prophylactic protocols and diagnostic assays for HBV infection.
COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (Australie)
WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (Australie)
GRAINS RESEARCH AND DEVELOPMENT CORPORATION (Australie)
MELBOURNE HEALTH (Australie)
Inventeur(s)
Tanner, Gregory John
Howitt, Crispin Alexander
Abrégé
The present invention relates to methods of producing a food or malt-base beverage suitable for consumption by a subject with Coeliac's disease, In particula the present invention relates to methods of producing a food or malt-based bevera with low levels of hordeins. Also provided are barley plants which produce grain th can be used in the methods of the invention.
COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (Australie)
WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (Australie)
GRAINS RESEARCH AND DEVELOPMENT CORPORATION (Australie)
MELBOURNE HEALTH (Australie)
Inventeur(s)
Tanner, Gregory John
Howitt, Crispin Alexander
Abrégé
The present invention relates to methods of producing a food or malt-base beverage suitable for consumption by a subject with Coeliac's disease, In particula the present invention relates to methods of producing a food or malt-based bevera with low levels of hordeins. Also provided are barley plants which produce grain th can be used in the methods of the invention.
A01H 5/00 - Angiospermes, c.-à-d. plantes à fleurs, caractérisées par leurs parties végétalesAngiospermes caractérisées autrement que par leur taxonomie botanique
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
The present invention relates generally to a method for the treatment of a hemoglobinopathic condition in mammalian subjects such as humans and medicaments useful for same.
ST. VINCENT'S HOSPITAL (MELBOURNE) LTD TRADING AS ST. VINCENT'S HOSPITAL MELBOURNE (Australie)
Inventeur(s)
Bartholomeusz, Angeline, Ingrid
Locarnini, Stephen
Ayres, Anna
Yuen, Lilly, Ka Wai
Angus, Peter, William
Sasadeusz, Joseph, John
Desmond, Paul
Tillman, Hans
Bock, Thomas
Sievert, William
Lewin, Sharon
Abrégé
The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. Vaccines and diagnostic assays are also contemplated herein.
C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification
C12Q 1/70 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des virus ou des bactériophages
21.
ANTIVIRAL RESISTANCE MUTANTS AND APPLICATIONS THEREOF
The present invention relates generally to viral variants exhibiting reduced sensitivity to agents such as nucleoside or nucleotide analogs or other DNA polymerase antagonists and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs or other DNA polymerase antagonists and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for and/or develop or design agents capable of inhibiting infection, replication and/or release of the virus.
ST. VINCENT'S HOSPITAL (MELBOURNE) LTD TRADING AS ST. VINCENT'S HOSPITAL MELBOURNE (Australie)
AUSTIN HEALTH (Australie)
Inventeur(s)
Bartholomeusz, Angeline, Ingrid
Locarnini, Stephen
Ayres, Anna
Littlejohn, Margaret
Desmond, Paul
Angus, Peter, William
Abrégé
The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for and/or develop or design agents capable of inhibiting infection, replication and/or release of the virus.
C12N 7/01 - Virus, p. ex. bactériophages, modifiés par l'introduction de matériel génétique étranger
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
C12Q 1/70 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des virus ou des bactériophages
C12N 15/01 - Préparation de mutants sans introduction de matériel génétique étrangerProcédés de criblage à cet effet
